Physician profile
Eva Manitius
NPI 1932162120
$2,784.49
in general payments reported to CMS, 2019-2025
19 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $173 · 2021: $485 · 2022: $584 · 2023: $515 · 2024: $439 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,233.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $909.70 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $681.52 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $426.67 | 2019-2025 | Breztri, Airsupra |
| Exact Sciences Corporation | $138.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Currax Pharmaceuticals LLC | $132.78 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $91.04 | 2024-2025 | Zoryve |
| Glaxosmithkline, LLC. | $73.05 | 2020-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Eisai INC. | $54.36 | 2019 | |
| Lilly USA, LLC | $44.26 | 2021-2023 | Mounjaro |
| Bausch Health US, LLC | $37.40 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.55 | 2021-2022 | |
| Allergan, INC. | $29.99 | 2019 | |
| Axsome Therapeutics, INC. | $28.73 | 2024 | Auvelity |
| Paratek Pharmaceuticals, INC. | $23.14 | 2023 | Nuzyra |
| Abbott Laboratories | $21.74 | 2024 | Freestyle Libre 3 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $18.13 | 2021 | |
| Genentech USA, INC. | $15.50 | 2019 | |
| Cequr Corporation | $12.57 | 2023 | Cequr Simplicity |
| Supernus Pharmaceuticals, INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Manitius listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.